Chemed Corp. (NYSE:CHE) EVP Spencer S. Lee sold 1,000 shares of Chemed Corp. stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $228.45, for a total transaction of $228,450.00. Following the completion of the sale, the executive vice president now owns 36,809 shares in the company, valued at approximately $8,409,016.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Chemed Corp. (NYSE:CHE) traded up $9.80 during mid-day trading on Friday, hitting $234.25. 46,180 shares of the stock were exchanged, compared to its average volume of 92,810. The stock has a market cap of $3,669.95, a P/E ratio of 28.31 and a beta of 1.14.

Chemed Corp. (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.15. Chemed Corp. had a net margin of 4.62% and a return on equity of 27.69%. The firm had revenue of $417.40 million for the quarter, compared to analysts’ expectations of $414.34 million. During the same quarter in the previous year, the business posted $1.73 EPS. The company’s quarterly revenue was up 6.3% on a year-over-year basis. research analysts expect that Chemed Corp. will post 4.73 earnings per share for the current year.

WARNING: “Insider Selling: Chemed Corp. (CHE) EVP Sells 1,000 Shares of Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/03/insider-selling-chemed-corp-che-evp-sells-1000-shares-of-stock.html.

Several analysts recently weighed in on CHE shares. TheStreet upgraded shares of Chemed Corp. from a “c+” rating to an “a-” rating in a report on Friday, October 27th. Zacks Investment Research upgraded shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $216.00 price target on the stock in a report on Monday, September 18th. BidaskClub cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Royal Bank Of Canada restated a “hold” rating and set a $209.00 target price on shares of Chemed Corp. in a report on Monday, July 31st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Chemed Corp. currently has a consensus rating of “Hold” and a consensus price target of $236.00.

Several hedge funds have recently made changes to their positions in CHE. Acrospire Investment Management LLC bought a new stake in shares of Chemed Corp. during the 2nd quarter valued at $120,000. Pacad Investment Ltd. boosted its holdings in shares of Chemed Corp. by 250.0% during the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after buying an additional 500 shares in the last quarter. IFP Advisors Inc boosted its holdings in shares of Chemed Corp. by 1,504.5% during the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock valued at $143,000 after buying an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Chemed Corp. by 12.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after buying an additional 83 shares in the last quarter. Finally, MCF Advisors LLC bought a new stake in shares of Chemed Corp. during the 3rd quarter valued at $152,000. Hedge funds and other institutional investors own 97.24% of the company’s stock.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Insider Buying and Selling by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.